SS
AKBA icon

SBI Securities’s Akebia Therapeutics AKBA Stock Holding History

SBI Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Sell
39
-4,500
-99% -$5.36K ﹤0.01% 3698
2026
Q1 		$6.31K Hold
4,539
– – ﹤0.01% 1933
2025
Q4 		$7.31K Sell
4,539
-14
-0.3% -$29 ﹤0.01% 1867
2025
Q3 		$12.4K Sell
4,553
-2,986
-40% -$9.93K ﹤0.01% 1662
2025
Q2 		$27.4K Sell
7,539
-94
-1% -$258 ﹤0.01% 1288
2025
Q1 		$14.7K Buy
7,633
+4,500
+144% +$9.19K ﹤0.01% 1448
2024
Q4 		$5.95K Buy
+3,133
New +$5.44K ﹤0.01% 1859

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SBI Securities's AKBA Position: Q2 2026 in Review

SBI Securities reduced its Akebia Therapeutics (AKBA) stake by 99% in Q2 2026, selling an estimated $5.36K and leaving 39 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #3698.

SBI Securities first reported a position in AKBA in Q4 2024 and has held it in 7 quarters since. The position peaked at $27.4K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • SBI Securities held 39 shares of Akebia Therapeutics worth $44 as of Q2 2026.
  • SBI Securities sold 4,500 Akebia Therapeutics shares in Q2 2026, an estimated $5.36K.
  • Akebia Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3698 holding.
  • SBI Securities first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Akebia Therapeutics position peaked at $27.4K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.